Kilpatrick's Allison Dobson and Raquel de Castro will analyze and provide strategic suggestions in light of five recent cases where the Federal Circuit generally applies more stringent requirements for sufficiency of Written Description and Enablement of pharmaceutical patent claims. Our speakers will distill practical lessons for drafting robust specifications and for attacking or defending validity in litigation.
Key Cases include:
-
Duke/Allergan v. Sandoz;
-
Seagen v. Daiichi Sankyo;
-
Teva v. Eli Lilly;
-
Wyeth LLC v. AstraZeneca; and,
-
Enanta Pharma. Inc. v. Pfizer Inc.
Event Details
Thursday, October 8, 2026
Zoom
12:00 p.m. - 1:00 p.m. Eastern
CLE Credit
To meet MCLE regulators’ attendance verification requirements for sponsors you must answer the poll questions during the program.
MCLE credit approval is pending. Credit generally is submitted, or certificates issued, within 60 days of post-program approval. CLE approval can take up to 90 days.
Kilpatrick Townsend & Stockton LLP will apply for CLE credit when eligible in California, Colorado, Georgia, Illinois, New York, North Carolina, Ohio, Texas, Virginia, and Washington. For states not listed, a Certificate of Attendance that lawyers may use to claim credit based on reciprocity or self-apply for credit will be provided.
We recommend you complete the program in one format only (live or on-demand) since many states do not allow attorneys to earn live and on-demand credit for the same program in the same compliance period. Virtual participation or on-demand credit is not eligible in PA.
Contact
Ainsley Fischman
Marketing & Business Development Coordinator
Speakers
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
